Coeptis Therapeutics Holdings, Inc. (COEP)
Apr 24, 2026 - COEP merged into ZSQR
16.40
+0.19 (1.17%)
Inactive · Last trade price on Apr 24, 2026
COEP Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 5.67 | 0.53 | 1.47 | 3.79 | 2.18 |
Short-Term Investments | 0.68 | - | - | - | - |
Cash & Short-Term Investments | 6.35 | 0.53 | 1.47 | 3.79 | 2.18 |
Cash Growth | 1091.80% | -63.73% | -61.25% | 73.95% | 140.26% |
Accounts Receivable | - | - | - | 0.01 | - |
Other Receivables | 0.01 | - | 0.04 | - | - |
Total Trade Receivables | 0.01 | - | 0.04 | 0.01 | - |
Other Current Assets | 0.99 | 0.52 | 0.24 | 0.14 | - |
Total Current Assets | 7.35 | 1.05 | 1.75 | 3.94 | 2.18 |
Net Property, Plant & Equipment | 0.03 | 0.07 | 0.11 | 0.07 | 0.03 |
Other Intangible Assets | 0.92 | 2.1 | 2.55 | 3.55 | 4.55 |
Long-Term Investments | 7.86 | 5.69 | - | - | - |
Other Long-Term Assets | - | - | 0.16 | 0.35 | - |
Total Assets | 16.15 | 8.91 | 4.57 | 7.92 | 6.77 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | - | 1.42 | 0.1 | 0.13 |
Accrued Expenses | - | - | 0.56 | 0.18 | 0.2 |
Short-Term Debt | 0.1 | 1.19 | 0.98 | 1.85 | 2.42 |
Current Portion of Leases | 0.02 | 0.04 | 0.04 | 0.04 | 0.01 |
Unearned Revenue | 0.6 | - | - | - | - |
Other Current Liabilities | 0.12 | 1.28 | - | - | - |
Total Current Liabilities | 0.84 | 2.51 | 2.99 | 2.17 | 2.76 |
Long-Term Debt | 0.15 | 0.15 | 0.15 | 0.15 | 1.65 |
Long-Term Leases | - | 0.02 | 0.06 | 0.01 | - |
Other Long-Term Liabilities | 0.17 | 0.36 | 0.56 | 1.13 | - |
Total Long-Term Liabilities | 0.32 | 0.53 | 0.77 | 1.29 | 1.65 |
Total Liabilities | 1.16 | 3.03 | 3.76 | 3.46 | 4.41 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | - | - | - | - | -0.25 |
Additional Paid-in Capital | -3.69 | -1.56 | 88.17 | 70.54 | 30.15 |
Retained Earnings | -109.95 | -98.04 | -87.36 | -66.09 | -27.55 |
Total Common Shareholders' Equity | 13.56 | 3.38 | 0.81 | 4.45 | 2.35 |
Minority Interest | 0.51 | 0.49 | - | - | - |
Shareholders' Equity | -113.13 | -99.11 | 0.81 | 4.45 | 2.35 |
Total Liabilities & Equity | -111.98 | -96.07 | 4.57 | 7.92 | 6.77 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.27 | 1.4 | 1.22 | 2.06 | 4.08 |
Net Cash (Debt) | 6.08 | -0.87 | 0.24 | 1.73 | -1.9 |
Net Cash Growth | - | - | -85.88% | - | - |
Net Cash Per Share | 1.44 | -0.45 | 0.19 | 1.35 | -3.49 |
Book Value | 13.56 | 3.38 | 0.81 | 4.45 | 2.35 |
Book Value Per Share | 3.20 | 1.76 | 0.63 | 3.47 | 4.31 |
Tangible Book Value | 12.65 | 1.29 | -1.74 | 0.9 | -2.2 |
Tangible Book Value Per Share | 2.99 | 0.67 | -1.35 | 0.70 | -4.04 |